Assessment of AMG 420 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Stopped early · Phase 1
Conditions studied: Relapsed and/or Refractory Multiple Myeloma
In brief
To confirm the maximum tolerated dose (MTD) from the BI 836909 trial of 400 mcg/d, given as 28-day continuous intravenous infusion in patients with relapsed and/or refractory multiple myeloma, to test the 600 mcg/d dose, given as a 28-day continuous iV infusion.
Key facts
- Study ID
- NCT03836053
- Run by
- Amgen
- People needed
- 23
- Starts
- 2019-03-04
- Expected to finish
- 2022-04-21
- Last updated by the study team
- 2025-09-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Advocate Lutheran General Hospital — Park Ridge, Illinois, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Wake Forest Baptist Health — Winston-Salem, North Carolina, United States
- St Vincents Hospital Sydney — Darlinghurst, New South Wales, Australia
- St Vincents Hospital Melbourne — Fitzroy, VIC, Victoria, Australia
- Centres Hospitaliers Jolimont - Hopital de Jolimont — Haine Saint Paul - La Louviere, Belgium
- Centre Hospitalier Universitaire Dinant Godinne - Universite Catholique de Louvain Namur — Yvoir, Belgium
- National Hospital Organization Okayama Medical Center — Okayama, Okayama-ken, Japan
- Kantonsspital St Gallen — Sankt Gallen, Switzerland
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.